Xian Deng's questions to Genmab A/S (GMAB) leadership • Q1 2025
Question
Xian Deng from UBS requested a sales breakdown for EPKINLY between follicular lymphoma (FL) and DLBCL, along with physician feedback on its use in FL. She also asked about the expected duration of treatment for EPKINLY in the second-line FL setting.
Answer
CCO Brad Bailey declined to provide a specific sales split but noted robust uptake post-FL launch, with physicians valuing the dual indication, subcutaneous administration, and no hospitalization requirement. CMO Tahamtan Ahmadi clarified that the second-line FL study regimen has a fixed 12-month duration and that the regulatory submission is based on a compelling interim overall response rate.